Robert Schueler

TL;DR: This independent, contemporary registry shows that TMVR is associated with high immediate success, low complication rates, and sustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptoms.

TL;DR: Initial efficacy analysis showed encouraging reduction of TR, which may potentially result in improved clinical outcomes, and transcatheter treatment of TR with the MitraClip system seems to be safe and feasible in this cohort of preselected patients.

TL;DR: This study establishes feasibility of the Edwards PASCAL TMVr system with a high rate of technical success and reduction of mitral regurgitation severity, and further research is needed on procedural and long-term clinical outcomes.

TL;DR: Patients currently undergoing transcatheter tricuspid valve therapy are mostly high risk, with a functional etiology and very severe central regurgitation, and do not have severely impaired RV function, suggest initial results suggest that transcat heterogeneous valve therapy is feasible with different techniques, but clinical efficacy requires further investigation.

TL;DR: Six-month outcomes show that the transcatheter tricuspid valve reconstruction system performs as intended and appears to be safe in patients with symptomatic and moderate to severe functional TR.